Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial

Documenti analoghi

• Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same survival benefit?
  di: Jeffrey H. Lipton
  Pubblicazione: (2024)
• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
  di: Elias Jabbour, et al.
  Pubblicazione: (2024)
• Characteristics and outcomes of patients with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia after failure of a frontline ponatinib‐containing therapy
  di: Nicholas J. Short, et al.
  Pubblicazione: (2024)
• Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers
  di: Yasmin Abaza, et al.
  Pubblicazione: (2024)
• BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
  di: Camille Kockerols, et al.
  Pubblicazione: (2024)